Bioventus Inc.
BVS
$7.44
-$0.20-2.62%
NASDAQ
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Net Income | 129.04% | 46.07% | 97.44% | 33.94% | -597.69% |
| Total Depreciation and Amortization | -7.95% | 0.68% | 0.35% | -11.22% | -10.34% |
| Total Amortization of Deferred Charges | -- | -- | -16.67% | -- | -- |
| Total Other Non-Cash Items | -73.20% | 42.27% | 31.47% | 141.85% | 813.95% |
| Change in Net Operating Assets | -91.39% | -111.43% | -206.73% | 97.18% | 85.57% |
| Cash from Operations | 71.07% | -221.92% | 86.25% | 224.06% | 40.45% |
| Capital Expenditure | -787.01% | -183.85% | -55.56% | 96.86% | 94.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 11,216.22% | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,677.92% | 17.40% | 4,178.51% | 96.86% | -100.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 39.50% | -63.61% | -- | 100.00% | 86.29% |
| Issuance of Common Stock | 116.26% | -15.25% | 598.10% | 39.29% | 338.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5,678.95% | -575.20% | 2,603.49% | -13.69% | 91.05% |
| Cash from Financing | -86.91% | 122.32% | -306,007.14% | -95.60% | 87.40% |
| Foreign Exchange rate Adjustments | 148.21% | 179.04% | -660.60% | 205.91% | -274.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 48.19% | -59.27% | -114.72% | 532.47% | 138.51% |